secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2026-08-05T11:02:49+00:00
Accession:  0001193125-26-333813
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q32 Bio Q2 net loss $8.9M; positive bempikibart Phase 2a data; $200M offering
-----------------------------------------------------------------------------

- Net loss $8.9M ($0.44/share) vs $9.5M ($0.78) in Q2 2025; R&D expense $4.3M, G&A $4.9M.
- Cash $106.3M at June 30, 2026; combined with $200M July offering funds through Phase 3 topline.
- Bempikibart showed 35.3% mean SALT reduction at Week 36; 40% SALT-20 response (mITT) in SIGNAL-AA Part B.
- Registration-directed program for severe/very severe AA expected to start 1H2027, pending regulatory discussions.
- ADX-914-XL (half-life extended anti-IL-7Rα) advancing in preclinical development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000119312526333813/0001193125-26-333813-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000119312526333813/qttb-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-333813

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer